Results 151 to 160 of about 7,354 (172)

Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis: A Review of Registry-Based Evidence. [PDF]

J Clin Med
Salvatore D, Pepe A.
europepmc   +1 more source

Demonstrating Bioequivalence for a Lumacaftor Monosubstance Formulation Versus Orkambi^® (Lumacaftor/Ivacaftor) in Healthy Subjects. [PDF]

Drugs R D
Papaelias A, Lidington D, Bolz SS.
europepmc   +1 more source

Evaluating the effects of ivacaftor exposure on Staphylococcus aureus small colony variant development and antibiotic tolerance

Gretchen E Bollar, Katherine A. Shaffer, Johnathan D. Keith, Ashley M. Oden, Alexander E. Dowell, Kevin J. Ryan, Edward P. Acosta, Jennifer S. Guimbellot, Megan R. Kiedrowski, Susan E. Birket   +9 more
openalex   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on the small airways in cystic fibrosis. [PDF]

J Bras Pneumol
Silva SC, Barroso A, Cunha M, Fragoso E, Azevedo P.   +4 more
europepmc   +1 more source

Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Sleep Breath
Dietz-Terjung S, Straßburg S, Schöbel C, Schulte T, Dietz P, Gahbiche FE, Ortiz J, Taube C, Weinreich G, Sutharsan S, Welsner M.   +10 more
europepmc   +1 more source

Condition-dependent effects of Elexacaftor/Tezacaftor/Ivacaftor (Trikafta) on <i>Aspergillus fumigatus</i> growth. [PDF]

Microbiol Spectr
Biquand E, Khau S, Fouquenet D, Chouela Mbouwe S, Costes F, Drobecq L, Chesnay A, Desoubeaux G, Briard B.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2022
David P Nichols, Sonya L Heltshe, Scott H Donaldson   +2 more
exaly